Wednesday, July 8, 2026

biotech · Multiple Myeloma · Multiple Myeloma (MM) · CCCC

C4 Therapeutics

C4 Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

WATERTOWN, MA, USA HQ
2024 Founded
2 Employees
Public company Type
CCCC · NYSE Ticker
Company details
Status
Public
HQ
WATERTOWN, MA, USA
Founded
2024
Employees
2
Programs
4
Drugs
1
Patents
24
Intelligence · Clinical Programs

C4 Therapeutics projects

3 ClinicalTrials.gov programs sponsored by C4 Therapeutics.

C4 Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CFT1946

    C4 Therapeutics

    Solid Tumors

    phase 1 small molecule completed

    1 trial
  2. CFT8634

    C4 Therapeutics

    Synovial Sarcoma

    phase 1 small molecule terminated

    1 trial
  3. Cemsidomide

    C4 Therapeutics

    Multiple Myeloma (MM)

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does C4 Therapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.